Development of a Translational Assay for Identification and Quantitation of Orthologous Proteins to Aid Drug Development in Preclinical Models.
- 1Inoviv, Fox Court, 14 Gray's Inn Road, LondonWC1X 8HN, U.K.
- 2AviadoBio Ltd, 20 Water Street, LondonE14 5GX, U.K.
- 3Maurice Wohl Clinical Neuroscience Institute, 5 Cutcombe Road, LondonSE5 9RT, U.K.
Abstract
Unequivocal identification and reproducible quantitation of proteins are key components of research and development activity in drug discovery. In some cases, the target protein might be a protein highly conserved across species; antibody-based assays are not specific enough to discriminate between orthologues, thus forcing drug developers to use multiple analytical platforms across preclinical models. Here, we present a modular mass spectrometry-based assay for the analysis of orthologous proteins across species in the context of translational science using ataxin-2 (ATXN2) as an example. Instead of relying on recombinant proteins, we applied rational peptide design to target human, mouse, human/pig/non-human primates (NHP), or pan-species regions of the full-length protein. Specificity and sensitivity of the method were proven in wild-type and transgenic models. Dose-response upon treatment with different doses of an adeno-associated virus (AAV)-delivering microRNA (miRNA) targeting ATXN2 showed that knock-down at the transcript level was consistent with downregulation at the protein level, confirming the assay suitability for target engagement evaluation. Furthermore, the data presented here indicate that this method is readily transferable to minipigs, ensuring analytical continuity across preclinical studies. More broadly, this work provides a translational blueprint that can be adapted to other orthologues, reducing cost and timeline in drug development.
Related
- The Development and Optimization of Biogenic Molecularly Imprinted Sensors for the Sensitive and Selective Electroanalytical Quantitation of Met-Enkephalin
- Development and Evaluation of a Capillary Column GC-FID Identification Test for Sage Oil and Sage Water Listed in the Japanese Standards of Quasi-Drug Ingredients
- Conversational Multi-Agentic Network-Driven Disease Module Identification and Drug Repurposing Prediction With ChatDRex: Platform Development Study
- Mimetic tissue models for accurate lipid quantitation in fibrotic mouse heart by MALDI-MSI
- Novel method for extraction and quantitation of 6PPD-Q in solid matrices using ultrasonic-assisted extraction (UAE) and liquid chromatography-tandem mass spectrometry (LC-MS/MS).
BibTeX
@article{rougemont2026development,
title = {{Development of a Translational Assay for Identification and Quantitation of Orthologous Proteins to Aid Drug Development in Preclinical Models.}},
author = {Blandine Rougemont and Julie Borgel and Zoe Walker and Irene Zubiri and Ronan O'Cualain and Neda Ali Mohammadi Nafchi and Christopher E Shaw and Ernestas Sirka and John Isaac and Carlos J Miranda and Anna Ettorre},
journal = {Journal of proteome research},
year = {2026},
month = oct,
doi = {10.1021/acs.jproteome.5c01164},
url = {https://europepmc.org/article/MED/42918133},
note = {CC BY},
}
RIS
TY - JOUR
TI - Development of a Translational Assay for Identification and Quantitation of Orthologous Proteins to Aid Drug Development in Preclinical Models.
AU - Blandine Rougemont
AU - Julie Borgel
AU - Zoe Walker
AU - Irene Zubiri
AU - Ronan O'Cualain
AU - Neda Ali Mohammadi Nafchi
AU - Christopher E Shaw
AU - Ernestas Sirka
AU - John Isaac
AU - Carlos J Miranda
AU - Anna Ettorre
PY - 2026
DA - 2026/10/01
JO - Journal of proteome research
DO - 10.1021/acs.jproteome.5c01164
UR - https://europepmc.org/article/MED/42918133
AB - Unequivocal identification and reproducible quantitation of proteins are key components of research and development activity in drug discovery. In some cases, the target protein might be a protein highly conserved across species; antibody-based assays are not specific enough to discriminate between orthologues, thus forcing drug developers to use multiple analytical platforms across preclinical models. Here, we present a modular mass spectrometry-based assay for the analysis of orthologous proteins across species in the context of translational science using ataxin-2 (ATXN2) as an example. Instead of relying on recombinant proteins, we applied rational peptide design to target human, mouse, human/pig/non-human primates (NHP), or pan-species regions of the full-length protein. Specificity and sensitivity of the method were proven in wild-type and transgenic models. Dose-response upon treatment with different doses of an adeno-associated virus (AAV)-delivering microRNA (miRNA) targeting ATXN2 showed that knock-down at the transcript level was consistent with downregulation at the protein level, confirming the assay suitability for target engagement evaluation. Furthermore, the data presented here indicate that this method is readily transferable to minipigs, ensuring analytical continuity across preclinical studies. More broadly, this work provides a translational blueprint that can be adapted to other orthologues, reducing cost and timeline in drug development.
SN - 1535-3893
SN - 1535-3907
ER -